The predicted persistence and kinetics of antibody decline 9years after pre-school booster vaccination in UK children. 2016

Merryn Voysey, and Rama Kandasamy, and Ly-Mee Yu, and Martine Baudin, and Christine Sadorge, and Stéphane Thomas, and Tessa John, and Andrew J Pollard
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: Merryn.voysey@phc.ox.ac.uk.

Long term follow-up of vaccine trials is essential to establish the duration of protection. In the context of worldwide concern about rising pertussis incidence, estimates of antibody persistence after vaccination, which do not account for the rise in antibody due to natural boosting or infection, may overestimate the degree of protection afforded by pertussis vaccines. This was a 5year follow up study of a randomised controlled trial of diphtheria, tetanus, pertussis and polio booster vaccines in UK children aged 3.5-5years. Antibody persistence was measured at 1month, 1, 3, and 5years after vaccination and the kinetics of antibody decline were modelled longitudinally. Estimates of predicted antibody persistence 9years after the pre-school booster were derived from model parameters. Antibody levels 9years after vaccination were predicted to be above accepted thresholds for protection for diphtheria, tetanus and polio. Antibody responses to pertussis toxoid were undetectable in 49% of children at the 5year follow up visit, and responses were predicted to be undetectable in 69% (95% CI 45-88%) of children by the time of their teenage booster at 13-14years of age. There is no defined correlate of protection for pertussis. However, the large proportion of participants in this study with undetectable pertussis antibody levels at both measured and predicted timepoints suggests sub-optimal immunity in adolescence. Adding pertussis to the teenage booster for UK children as is done in other countries, would enhance immunity in adolescence.

UI MeSH Term Description Entries
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D011054 Poliovirus Vaccine, Inactivated A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS. Salk Vaccine,Inactivated Poliovirus Vaccine,Vaccine, Inactivated Poliovirus,Vaccine, Salk
D011055 Poliovirus Vaccine, Oral A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed) Sabin Vaccine,Oral Poliovirus Vaccine,Vaccine, Oral Poliovirus,Vaccine, Sabin
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006113 United Kingdom Country in northwestern Europe including Great Britain and the northern one-sixth of the island of Ireland, located between the North Sea and north Atlantic Ocean. The capital is London. Great Britain,Isle of Man

Related Publications

Merryn Voysey, and Rama Kandasamy, and Ly-Mee Yu, and Martine Baudin, and Christine Sadorge, and Stéphane Thomas, and Tessa John, and Andrew J Pollard
January 2019, Human vaccines & immunotherapeutics,
Merryn Voysey, and Rama Kandasamy, and Ly-Mee Yu, and Martine Baudin, and Christine Sadorge, and Stéphane Thomas, and Tessa John, and Andrew J Pollard
May 1993, The Journal of infectious diseases,
Merryn Voysey, and Rama Kandasamy, and Ly-Mee Yu, and Martine Baudin, and Christine Sadorge, and Stéphane Thomas, and Tessa John, and Andrew J Pollard
March 2018, The Journal of infection,
Merryn Voysey, and Rama Kandasamy, and Ly-Mee Yu, and Martine Baudin, and Christine Sadorge, and Stéphane Thomas, and Tessa John, and Andrew J Pollard
June 2007, Vaccine,
Merryn Voysey, and Rama Kandasamy, and Ly-Mee Yu, and Martine Baudin, and Christine Sadorge, and Stéphane Thomas, and Tessa John, and Andrew J Pollard
July 2019, Vaccine,
Merryn Voysey, and Rama Kandasamy, and Ly-Mee Yu, and Martine Baudin, and Christine Sadorge, and Stéphane Thomas, and Tessa John, and Andrew J Pollard
October 2014, Vaccine,
Merryn Voysey, and Rama Kandasamy, and Ly-Mee Yu, and Martine Baudin, and Christine Sadorge, and Stéphane Thomas, and Tessa John, and Andrew J Pollard
March 2002, Vaccine,
Merryn Voysey, and Rama Kandasamy, and Ly-Mee Yu, and Martine Baudin, and Christine Sadorge, and Stéphane Thomas, and Tessa John, and Andrew J Pollard
February 2006, Vaccine,
Merryn Voysey, and Rama Kandasamy, and Ly-Mee Yu, and Martine Baudin, and Christine Sadorge, and Stéphane Thomas, and Tessa John, and Andrew J Pollard
November 2022, Vaccines,
Merryn Voysey, and Rama Kandasamy, and Ly-Mee Yu, and Martine Baudin, and Christine Sadorge, and Stéphane Thomas, and Tessa John, and Andrew J Pollard
September 2007, The Pediatric infectious disease journal,
Copied contents to your clipboard!